UPLIZNA® (inebilizumab-cdon) Pivotal Trial Publication Integrating MRI and Biomarker Evaluation Shows Accuracy and Uniformity of Attack Diagnoses for Neuromyelitis Optica Spectrum Disorder (NMOSD)

-- Findings published in the Multiple Sclerosis Journal provide early validation of a process that could inform new clinical standards to improve attack diagnosis and treatment decision-making --

... | June 12, 2023

Related Keywords

United States ,Kristina Patterson ,Neuroimmunol Neuroinflamm ,Brian Weinshenker ,Twitter ,Facebook ,Linkedin ,Nasdaq ,Drug Administration ,Instagram ,Exchange Commission ,University Of Virginia School Medicine ,Horizon Therapeutics ,Multiple Sclerosis ,Virginia School ,Neuromyelitis Optica Spectrum Disorder ,Hepatitisb Virus ,Progressive Multifocal Leukoencephalopathy ,Full Prescribing Information ,United States Securities ,Accessed April ,Scler Relat ,